Patents by Inventor William L. Klein
William L. Klein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11541086Abstract: Provided herein are antibodies against amyloid-beta (A?) oligomers, and methods of use thereof for the treatment of Alzheimer's disease (AD). In particular, neuronal expression of single-chain variable fragment (scFv) antibodies against A? oligomers is provided as a therapeutic approach in the treatment of AD.Type: GrantFiled: March 16, 2020Date of Patent: January 3, 2023Assignee: Northwestern UniveristyInventors: William L. Klein, Diana Jerusalinsky, Sergio T. Ferreira, Maria Clara Selles, Adriano S. Sebollela
-
Publication number: 20210386879Abstract: A method for detecting soluble oligomeric amyloid ? in a subject is provided.Type: ApplicationFiled: August 25, 2021Publication date: December 16, 2021Inventors: Grant A. Krafft, William L. Klein, Brett A. Chromy, Lei Chang, Mary P. Lambert, Kirsten L. Viola
-
Publication number: 20200289589Abstract: Provided herein are antibodies against amyloid-beta (A?) oligomers, and methods of use thereof for the treatment of Alzheimer's disease (AD). In particular, neauronal expression of single-chain variable fragment (scFv) antibodies against A? oligomers is provided as a therapeutic approach in the treatment of AD.Type: ApplicationFiled: March 16, 2020Publication date: September 17, 2020Inventors: William L. Klein, Diana Jerusalinsky, Sergio T. Ferreira, Maria Clara Selles, Adriano S. Sebollela
-
Publication number: 20170209604Abstract: A method for detecting soluble oligomeric amyloid ? in a subject using, e.g., PET is provided.Type: ApplicationFiled: April 11, 2017Publication date: July 27, 2017Applicant: Northwestern UniversityInventors: Grant A. Krafft, William L. Klein, Brett A Chromy, Lei Chang, Mary P. Lambert, Kirsten L. Viola
-
Publication number: 20160213794Abstract: The invention herein comprises amyloid beta-derived diffusible ligands (ADDLs), compositions comprising ADDLs, ADDL-surrogates, ADDL-binding molecules, and methods of using any of the foregoing compounds and compositions. ADDLs comprise amyloid ? protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of generating ADDL-specific antibodies and methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.Type: ApplicationFiled: March 29, 2016Publication date: July 28, 2016Inventors: Grant A. Krafft, William L. Klein, Brett A. Chromy, Lei Chang, Mary P. Lambert, Kirsten L. Viola
-
Patent number: 9095629Abstract: The present invention relates to magnetic nanostructures as theranostic agents, which provide dual function as diagnostic and therapeutic agents. In particular, the present invention relates to compositions comprising magnetic nanostructures and their use as targeted therapeutic agents for cancers (e.g., medulloblastoma) and Alzheimer's disease and related diseases and conditions.Type: GrantFiled: November 1, 2010Date of Patent: August 4, 2015Assignees: NORTHWESTERN UNIVERSITY, ANN & ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGOInventors: Vinayak P. Dravid, Saurabh Sharma, Tadanori Tomita, Kirsten L. Viola, William L. Klein
-
Patent number: 8889138Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: GrantFiled: October 11, 2010Date of Patent: November 18, 2014Assignees: Merck Sharp & Dohme Corp., Northwestern UniversityInventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Elizabeth Chen Dodson, Gene Kinney, William L Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kirsten Viola, Lei Chang
-
Publication number: 20140322731Abstract: The invention herein comprises amyloid beta-derived diffusible ligands (ADDLs), compositions comprising ADDLs, ADDL-surrogates, ADDL-binding molecules, and methods of using any of the foregoing compounds and compositions. ADDLs comprise amyloid ? protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of generating ADDL-specific antibodies and methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.Type: ApplicationFiled: February 26, 2014Publication date: October 30, 2014Applicant: Northwestern UniversityInventors: Grant A. Krafft, William L. Klein, David W. Summa, Brett A. Chromy, Lei Chang, Mary P. Lambert, Kirsten L. Viola, Yue Song Gong
-
Publication number: 20130330837Abstract: Disclosed herein are antibodies that bind with high specificity to soluble oligomers of amyloid ? (Abeta) and methods utilizing such antibodies. The antibodies are able to distinguish between Alzheimer's Disease (AD) and control human brain extracts. The antibodies identify endogenous Abeta oligomers in AD brain slices and also bind to Abeta oligomers on cultured hippocampal cells. The antibodies neutralize endogenous Abeta oligomers and Abeta oligomers produced in solution.Type: ApplicationFiled: July 16, 2013Publication date: December 12, 2013Applicants: Acumen Pharmaceuticals, Inc., Northwestern UniversityInventors: Mary P. Lambert, Pauline T. Velasco, Lei Chang, Kirsten L. Viola, Sara J. Fernandez, Pascale N. Lacor, Daliya Khuon, Yuesong Gong, William L. Klein, Grant A. Krafft
-
Publication number: 20130236466Abstract: The invention herein comprises amyloid beta-derived diffusible ligands (ADDLs), compositions comprising ADDLs, ADDL-surrogates, ADDL-binding molecules, and methods of using any of the foregoing compounds and compositions. ADDLs comprise amyloid ? protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of generating ADDL-specific antibodies and methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.Type: ApplicationFiled: November 14, 2012Publication date: September 12, 2013Applicant: NORTHWESTERN UNIVERSITYInventors: Grant A. Krafft, William L. Klein, Brett A. Chromy, Lei Chang, Mary P. Lambert, Kirsten L. Viola
-
Patent number: 8507206Abstract: Disclosed herein are antibodies that bind with high specificity to soluble oligomers of amyloid ? (Abeta) and methods of employing those antibodies. The antibodies are able to distinguish between Alzheimer's Disease (AD) and control human brain extracts. The antibodies identify endogenous Abeta oligomers in AD brain slices and also bind to Abeta oligomers on cultured hippocampal cells. The antibodies neutralize endogenous Abeta oligomers and Abeta oligomers produced in solution.Type: GrantFiled: July 5, 2005Date of Patent: August 13, 2013Assignees: Northwestern University, Acumen Pharmaceuticals, Inc.Inventors: Mary P Lambert, Pauline T. Velasco, Lei Chang, Kirsten L. Viola, Sara J. Fernandez, Pascale N. Lacor, Daliya Khuon, Yuesong Gong, William L. Klein, Grant A. Krafft
-
Publication number: 20120308657Abstract: The present invention relates to magnetic nanostructures as theranostic agents, which provide dual function as diagnostic and therapeutic agents. In particular, the present invention relates to compositions comprising magnetic nanostructures and their use as targeted therapeutic agents for cancers (e.g., medulloblastoma) and Alzheimer's disease and related diseases and conditions.Type: ApplicationFiled: November 1, 2010Publication date: December 6, 2012Applicant: NORTHWESTERN UNIVERSITYInventors: Vinayak P. Dravid, Saurabh Sharma, Tadanori Tomita, Kirsten L. Viola, William L. Klein
-
Patent number: 8128930Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: GrantFiled: July 1, 2010Date of Patent: March 6, 2012Assignees: Northwestern University, Merck Sharp & Dohme Corp.Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Lei Chang, Elizabeth Chen Dodson, Gene Kinney, William L. Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kristen Viola
-
Publication number: 20110159013Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: ApplicationFiled: October 11, 2010Publication date: June 30, 2011Applicant: Merck & Co., Inc.Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Elizabeth Chen Dodson, Gene Kinney, William L. Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kirsten Viola, Lei Chang
-
Patent number: 7964359Abstract: The present invention relates to methods for enhancing the cellular uptake and clearance of soluble oligomeric A? peptide assemblies from the environment surrounding both neuronal and non-neuronal cells. Oligomeric A? peptide assembly uptake and clearance is achieved via an agent that enhances insulin receptor signaling. Such ADDL uptake enhancers represent effective anti-ADDL therapeutics for use in the therapeutic treatment and/or prophylactic treatment of diseases including Alzheimer's disease, Down's syndrome, and the like, in which compromised nerve cell function is linked to the formation and/or the activity of soluble oligomeric A? peptide assemblies, also known as ADDLs, and ADDL-related assemblies.Type: GrantFiled: May 11, 2007Date of Patent: June 21, 2011Assignees: Acumen Pharmaceuticals, Inc., Northwestern UniversityInventors: Wei-Qin Zhao, Grant A. Krafft, William L. Klein
-
Patent number: 7811563Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tauphosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: GrantFiled: October 21, 2005Date of Patent: October 12, 2010Assignees: Northwestern University, Merck & Co., Inc.Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Elizabeth Chen Dodson, Gene Kinney, William L Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kirsten Viola, Lei Chang
-
Patent number: 7638283Abstract: The invention described in this disclosure involves a new composition of matter, amyloid beta-derived dementing ligands (ADDL's). ADDLs consist of amyloid ? peptide assembled into soluble globular non-fibrillar oligomeric structures that are capable of activating specific cellular processes. The invention further encompasses methods for assaying the formation, presence, receptor protein binding and cellular activities of ADDLs. The invention further encompasses assay methods and inhibitor molecules for cellular signaling molecules activated by ADDLs. Also described are molecules that block proteins that promote the formation of ADDLs.Type: GrantFiled: May 16, 2005Date of Patent: December 29, 2009Assignees: Northwestern University, University of Southern CaliforniaInventors: Grant A. Krafft, William L. Klein, Brett A. Chromy, Mary P. Lambert, Caleb E. Finch, Todd Morgan, Pat Wals, Irina Rozovsky, Ann Barlow
-
Publication number: 20090285804Abstract: The invention herein comprises antibodies that bind to amyloid beta-derived diffusible ligands (ADDLs). ADDLs comprise amyloid ? protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes.Type: ApplicationFiled: June 17, 2009Publication date: November 19, 2009Inventors: William L. Klein, Grant A. Krafft, Mary P. Lambert, Kirsten L. Viola, Brett A. Chromy, Lei Chang
-
Publication number: 20080306074Abstract: Disclosed and claimed herein are compositions comprising ADDL receptors, related compositions, and related methods. ADDL receptors are typically, but perhaps not exclusively, localized at the post-synaptic density (PSD) of neuronal cells. Related compositions include, but are not limited to, compounds that affect, positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise. Related methods include, but are not limited to, procedures to screen for compounds that affect, either positively or negatively, ADDL binding to neuronal cells, either via one or more receptors localized at the post-synaptic density (PSD) or otherwise.Type: ApplicationFiled: May 16, 2005Publication date: December 11, 2008Inventors: Pascale N. Lacor, Kirsten L. Viola, Mary P. Lambert, Yeusong Gong, Lei Chang, Pauline T. Velasco, Eileen H. Bigio, Maria C. Buniel, Sara J. Fernandez, Jasna Jerecic, Susan Catalano, Todd Pray, Ray Lowe, Grant A. Krafft, William L. Klein
-
Patent number: 7461640Abstract: A cooling system comprises a cooler with a hot-side passage extending between hot-side inlet and outlets. The cooler further includes a cooling passage extending between cold-side inlet and outlets. A cooling medium is disposed within the cooling passage, and is in contact with the hot-side passage to reduce the temperature of the gas or liquid passing through the hot-side passage. The cooling system is configured to regulate the condition of the cooling medium within the cooler to reduce/eliminate unwanted boiling of the cooling medium being within the cooler. The cooling system can include controller that provides an output signal in response to a detected condition of the cooling medium, and a device that receives the output signal and changes the operation of the cooling system and/or operation of an internal combustion engine to reduce the occurrence of unwanted cooling medium boiling within the cooler.Type: GrantFiled: September 20, 2007Date of Patent: December 9, 2008Assignee: Honeywell International, Inc.Inventors: Keith Agee, Richard P. Beldam, William L. Klein